Isabelle Cloutier

Mrs. Isabelle Cloutier


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Open access
SCSonia Corbin
Sonia Corbin
MLMaude Lavallée
Maude Lavallée
PPPallavi Pradhan
Pallavi Pradhan
MTMagalie Thibault
Magalie Thibault
JMJulie Méthot
Julie Méthot
JLJacinthe Leclerc
Jacinthe Leclerc
Assessing the causality of a drug product-related adverse event (AE) is a very important aspect of pharmacovigilance. However, it is unclear whether AEs are investigated for causality in a hospital setting. The aims of this study were to (1) evaluate the proportion of AEs for which causality is sought and (2) list the causality assessment (CA) tools used by healthcare professionals. This retrospective study includes 500 randomized patients (125 patients/year) admitted to a tertiary care academic hospital between 2018 and 2021. Electronic medical records were reviewed and relevant variables were extracted: (1) demographic, (2) hospitalization, (3) drug product, (4) AE, and (5) CA. A descriptive analysis was carried out (median, minimum–maximum, proportion) to characterize our sample. The characteristic of our sample was as follows: median age 69 years old (range: 21–96 years), 43.6% female, median comorbidities/patient 4 (0–12), and median hospital stay of 3 days (1–19). We identified a total of 9568 drug products and 2541 AEs, among these, 302 (8.4%) were serious AEs. No CA ( n = 0) or CA tools ( n = 0) were found in our sample. In this study, we report that no AEs, whether serious or non-serious, were subject to documented CA. Key points: Adverse events among drug users are frequent during hospital stay. Causality assessment of adverse events was poorly documented by healthcare professionals in a hospital setting.

12 August 2026 in Biomed
Verified
Journal Article
Open access
PDF file
APAlexandra Porlier
Alexandra Porlier
SPSylvie Pilote
Sylvie Pilote
BDBenoit Drolet
Benoit Drolet
ICIsabelle Cloutier
Isabelle Cloutier
AVAudrey Vachon
Audrey Vachon
CSChantale Simard
Chantale Simard
Background: Ceftobiprole medocaril (Zevtera®) is an injectable broad-spectrum antibiotic. Objective: We aim to show that ceftobiprole initiated in hospital may be continued at home through Outpatient Parenteral Antibiotic Therapy (OPAT). Methods: Solutions of ceftobiprole at 2.0 and 2.8 mg/mL were prepared in PVC bags from 500 mg vials and stored at room temperature (RT) or 4 °C. Each sample was analyzed in triplicate samples using high-performance liquid chromatography (HPLC) at multiple time points over a 120 h period. Additionally, 2.5 mg/mL ceftobiprole solutions were prepared in Intermate® infusion devices (n = 3 preparations) and stored at 4 °C. Samples were collected on multiple days from Day 0 to Day 9, both immediately post-refrigeration and after 8 h at RT and analyzed in triplicate. Results: PVC bag solutions retained ≥90% of their initial concentrations. At RT, residual concentration was 90.9% (2.0 mg/mL) and 92.0% (2.8 mg/mL) after 24 h. At 4 °C, the 2.0 mg/mL formulation retained 90.8% after 120 h, and the 2.8 mg/mL formulation retained 90.2% after 96 h. Intermate® devices stored nine days at 4 °C and exposed to RT for 8 h retained ≥90% of the initial concentration of ceftobiprole (2.5 mg/mL; 93.3% before RT exposure; 91.1% after). Conclusions: Ceftobiprole medocaril exhibits sufficient physicochemical stability for OPAT use in PVC bags and Intermate® infusion device under tested conditions.